Giampiero Girolomoni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1700072/publications.pdf

Version: 2024-02-01

293 papers

14,170 citations

²⁶⁶³⁰ 56
h-index

26613 107 g-index

299 all docs

299 docs citations

times ranked

299

12516 citing authors

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Consensusâ€based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 657-682. | 2.4 | 727 |
| 2 | Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions. Journal of Investigative Dermatology, 2010, 130, 1785-1796. | 0.7 | 554 |
| 3 | Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1284-1293. | 5.7 | 546 |
| 4 | Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case?control study. British Journal of Dermatology, 2007, 157, 68-73. | 1.5 | 543 |
| 5 | Consensusâ€based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: partÂll. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 850-878. | 2.4 | 519 |
| 6 | Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. Journal of the American Academy of Dermatology, 2014, 70, 871-881.e30. | 1.2 | 423 |
| 7 | Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderateâ€toâ€severe plaque psoriasis over 52Âweeks: a phase III, randomized controlled trial (ESTEEM 2). British Journal of Dermatology, 2015, 173, 1387-1399. | 1.5 | 384 |
| 8 | The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. Frontiers in Immunology, 2018, 9, 1549. | 4.8 | 279 |
| 9 | Interleukin-17 is Produced by Both Th1 and Th2 Lymphocytes, and Modulates Interferon- \hat{I}^3 - and Interleukin-4-Induced Activation of Human Keratinocytes. Journal of Investigative Dermatology, 2000, 115, 81-87. | 0.7 | 256 |
| 10 | IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. Journal of Immunology, 1999, 162, 494-502. | 0.8 | 254 |
| 11 | Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Annals of the Rheumatic Diseases, 2008, 67, 26-30. | 0.9 | 249 |
| 12 | Dendritic cells as a major source of macrophage-derived chemokine/CCL22in vitro andin vivo. European Journal of Immunology, 2001, 31, 812-822. | 2.9 | 246 |
| 13 | Drug-induced lupus erythematosus. Archives of Dermatological Research, 2009, 301, 99-105. | 1.9 | 221 |
| 14 | Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. Journal of Hepatology, 2009, 51, 758-764. | 3.7 | 217 |
| 15 | Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 742-750. | 5.7 | 211 |
| 16 | Psoriasis and the metabolic syndrome. Clinics in Dermatology, 2018, 36, 21-28. | 1.6 | 211 |
| 17 | The role of <scp>IL</scp> â€23 and the <scp>IL</scp> â€23/ <scp>T_H</scp> 17 immune axis in the pathogenesis and treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1616-1626. | 2.4 | 187 |
| 18 | Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin Journal of Clinical Investigation, 1997, 99, 3009-3017. | 8.2 | 183 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Prevalence of symptoms experienced by patients with different clinical types of psoriasis. British Journal of Dermatology, 2004, 151, 594-599. | 1.5 | 174 |
| 20 | Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). Journal of the American Academy of Dermatology, 2015, 73, 27-36.e1. | 1.2 | 171 |
| 21 | Anti–tumour necrosis factorâ€Î± therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 341-344. | 2.4 | 166 |
| 22 | Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis. Npj Biofilms and Microbiomes, 2017, 3, 14. | 6.4 | 159 |
| 23 | Italian guidelines on the systemic treatments of moderateâ€ŧoâ€severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 774-790. | 2.4 | 140 |
| 24 | Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the populationâ€based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2002-2010. | 2.4 | 139 |
| 25 | Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. British Journal of Dermatology, 2013, 169, 666-672. | 1.5 | 138 |
| 26 | Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. British Journal of Dermatology, 2018, 178, 768-775. | 1.5 | 127 |
| 27 | European consensusâ€based (S2k) Guideline on the Management of Herpes Zoster – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. Journal of the European Academy of Dermatology and Venereology. 2017. 31. 20-29. | 2.4 | 125 |
| 28 | Psoriasis: rationale for targeting interleukin-17. British Journal of Dermatology, 2012, 167, 717-724. | 1.5 | 120 |
| 29 | Drug-induced morphea: Report of a case induced by balicatib and review of the literature. Journal of the American Academy of Dermatology, 2008, 59, 125-129. | 1.2 | 106 |
| 30 | Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2399-2404. | 2.4 | 104 |
| 31 | The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. British Journal of Dermatology, 2020, 182, 1331-1342. | 1.5 | 102 |
| 32 | The contribution of keratinocytes to the pathogenesis of atopic dermatitis. European Journal of Dermatology, 2006, 16, 125-31. | 0.6 | 100 |
| 33 | Interstitial granulomatous dermatitis: a distinct entity with characteristic histological and clinical pattern. British Journal of Dermatology, 2012, 166, 775-783. | 1.5 | 99 |
| 34 | Treatment Approaches to Moderate to Severe Psoriasis. International Journal of Molecular Sciences, 2017, 18, 2427. | 4.1 | 96 |
| 35 | Cutaneous manifestations of SARS oVâ€⊋ infection: a clinical update. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2499-2504. | 2.4 | 96 |
| 36 | Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy. Oncologist, 2011, 16, 228-238. | 3.7 | 94 |

| # | Article | IF | Citations |
|----|--|------|-----------|
| 37 | The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis. International Journal of Molecular Sciences, 2019, 20, 3318. | 4.1 | 91 |
| 38 | Chromatin remodelling and autocrine TNF $\hat{l}\pm$ are required for optimal interleukin-6 expression in activated human neutrophils. Nature Communications, 2015, 6, 6061. | 12.8 | 87 |
| 39 | Vasculitis as an adverse event following immunization – Systematic literature review. Vaccine, 2016, 34, 6641-6651. | 3.8 | 87 |
| 40 | Psoriasis and Atherothrombotic Diseases: Disease-Specific and Non–Disease-Specific Risk Factors. Seminars in Thrombosis and Hemostasis, 2009, 35, 313-324. | 2.7 | 86 |
| 41 | Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 918-924. | 2.4 | 85 |
| 42 | Biologic therapies in psoriasis: A new therapeutic approach. Autoimmunity Reviews, 2007, 6, 515-519. | 5.8 | 83 |
| 43 | Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. Frontiers in Pharmacology, 2020, 11, 117. | 3.5 | 80 |
| 44 | Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e30-41. | 2.4 | 75 |
| 45 | The epidemiology of atopic dermatitis in Italian schoolchildren. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 420-425. | 5.7 | 74 |
| 46 | Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. European Journal of Dermatology, 2005, 15, 279-83. | 0.6 | 73 |
| 47 | Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity, 2010, 43, 215-219. | 2.6 | 72 |
| 48 | Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Journal of Dermatological Treatment, 2020, 31, 606-614. | 2.2 | 72 |
| 49 | The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases. International Journal of Immunopathology and Pharmacology, 2014, 27, 1-10. | 2.1 | 69 |
| 50 | Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities. Frontiers in Medicine, 2015, 2, 1. | 2.6 | 68 |
| 51 | The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmunity Reviews, 2014, 13, 751-755. | 5.8 | 67 |
| 52 | Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. Journal of Dermatological Treatment, 2021, 32, 507-513. | 2.2 | 67 |
| 53 | Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, realâ€life study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 958-964. | 2.4 | 66 |
| 54 | Pruritus as a Distinctive Feature of Type 2 Inflammation. Vaccines, 2021, 9, 303. | 4.4 | 66 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Adalimumab in the Treatment of Immune-Mediated Diseases. International Journal of Immunopathology and Pharmacology, 2014, 27, 33-48. | 2.1 | 65 |
| 56 | Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections. Vaccines, 2020, 8, 517. | 4.4 | 65 |
| 57 | European consensusâ€based (S2k) Guideline on the Management of Herpes Zoster – guided by the European Dermatology Forum (<scp>EDF</scp>) in cooperation with the European Academy of Dermatology and Venereology (<scp>EADV</scp>), Part 1: Diagnosis. Journal of the European Academy of Dermatology and Venereology. 2017. 31. 9-19. | 2.4 | 62 |
| 58 | Targeting tumor necrosis factor \hat{l}_{\pm} in psoriasis and psoriatic arthritis. Expert Opinion on Therapeutic Targets, 2008, 12, 1085-1096. | 3.4 | 58 |
| 59 | Urticarial lesions: If not urticaria, what else? The differential diagnosis of urticaria. Journal of the American Academy of Dermatology, 2010, 62, 541-555. | 1.2 | 58 |
| 60 | Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines. Journal of Clinical Medicine, 2021, 10, 5344. | 2.4 | 58 |
| 61 | Psoriasis and systemic inflammation: underdiagnosed enthesopathy. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 3-8. | 2.4 | 57 |
| 62 | Urticarial lesions: If not urticaria, what else? The differential diagnosis of urticaria. Journal of the American Academy of Dermatology, 2010, 62, 557-570. | 1.2 | 57 |
| 63 | <p>Targeting IL-4 for the Treatment of Atopic Dermatitis</p> . ImmunoTargets and Therapy, 2020, Volume 9, 151-156. | 5.8 | 56 |
| 64 | Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Annals of the Rheumatic Diseases, 2022, 81, 68-73. | 0.9 | 53 |
| 65 | The patientâ€reported disease burden in adults with atopic dermatitis: a crossâ€sectional study in Europe and Canada. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1026-1036. | 2.4 | 52 |
| 66 | Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. British Journal of Dermatology, 2014, 170, 591-598. | 1.5 | 51 |
| 67 | Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. Journal of the American Academy of Dermatology, 2020, 83, 39-45. | 1.2 | 51 |
| 68 | Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab. International Journal of Immunopathology and Pharmacology, 2014, 27, 11-32. | 2.1 | 50 |
| 69 | Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. Journal of Dermatological Treatment, 2015, 26, 103-112. | 2.2 | 50 |
| 70 | Nonâ€alcoholic fatty liver disease fibrosis score in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 282-287. | 2.4 | 50 |
| 71 | A Reappraisal on the Potential Ability of Human Neutrophils to Express and Produce IL-17 Family Members In Vitro: Failure to Reproducibly Detect It. Frontiers in Immunology, 2018, 9, 795. | 4.8 | 49 |
| 72 | Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. Journal of the American Academy of Dermatology, 2020, 83, 285-287. | 1.2 | 49 |

| # | Article | IF | Citations |
|----|---|-----|-----------|
| 73 | Pimecrolimus in dermatology: atopic dermatitis and beyond. International Journal of Clinical Practice, 2005, 59, 969-974. | 1.7 | 47 |
| 74 | Modulation of cytokine expression in mouse dendritic cell clones. European Journal of Immunology, 1994, 24, 2522-2526. | 2.9 | 46 |
| 75 | Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. Immunologic Research, 2013, 56, 382-389. | 2.9 | 46 |
| 76 | Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 96, 167-182. | 4.4 | 46 |
| 77 | Cutaneous manifestations of Churg–Strauss syndrome: report of two cases and review of the literature. Clinical Rheumatology, 2011, 30, 573-580. | 2.2 | 45 |
| 78 | Hyperuricemia in patients with chronic plaqueÂpsoriasis. Journal of the American Academy of Dermatology, 2014, 70, 127-130. | 1.2 | 45 |
| 79 | Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. Acta Dermato-Venereologica, 2021, 101, adv00402. | 1.3 | 45 |
| 80 | European Guidelines (S1) on the use of highâ€dose intravenous immunoglobulin in dermatology. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1657-1669. | 2.4 | 43 |
| 81 | Advanced Glycation End Products in the Pathogenesis of Psoriasis. International Journal of Molecular Sciences, 2017, 18, 2471. | 4.1 | 43 |
| 82 | Nomenclature and clinical phenotypes of atopic dermatitis. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110029. | 2.5 | 43 |
| 83 | Subcutaneous sarcoidosis: report of two cases and review of the literature. Clinical Rheumatology, 2011, 30, 1123-1128. | 2.2 | 42 |
| 84 | Drugâ€induced lupus erythematosus with emphasis on skin manifestations and the role of antiâ€₹NFα agents. JDDG - Journal of the German Society of Dermatology, 2012, 10, 889-897. | 0.8 | 42 |
| 85 | Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacology and Immunotoxicology, 2012, 34, 548-560. | 2.4 | 41 |
| 86 | Italian expert consensus for the management of actinic keratosis in immunocompetent patients. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1077-1084. | 2.4 | 41 |
| 87 | Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. Vaccine, 2016, 34, 6634-6640. | 3.8 | 41 |
| 88 | Considerations for Systemic Treatment of Psoriasis in Obese Patients. American Journal of Clinical Dermatology, 2016, 17, 609-615. | 6.7 | 40 |
| 89 | Congenital Dermatofibrosarcoma Protuberans. Pediatric Dermatology, 1993, 10, 40-42. | 0.9 | 39 |
| 90 | Perception of Disease and Doctor-Patient Relationship Experienced by Patients with Psoriasis. American Journal of Clinical Dermatology, 2009, 10, 325-330. | 6.7 | 39 |

| # | Article | IF | CITATIONS |
|-----|--|--------------|-----------|
| 91 | Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study. American Journal of Clinical Dermatology, 2021, 22, 581-586. | 6.7 | 38 |
| 92 | The Role of Interleukin-17A in Psoriatic Disease. BioDrugs, 2014, 28, 487-497. | 4.6 | 37 |
| 93 | The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey. Dermatology and Therapy, 2021, 11, 117-130. | 3.0 | 37 |
| 94 | Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common coâ€morbidities in patients with moderateâ€toâ€severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1661-1669. | 2.4 | 36 |
| 95 | Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. British Journal of Dermatology, 2015, 172, 1613-1620. | 1.5 | 36 |
| 96 | Distribution of HLA class II molecules in epidermal Langerhans cellsin situ. European Journal of Immunology, 1995, 25, 520-525. | 2.9 | 35 |
| 97 | Cutaneous manifestations of adult-onset Still's disease: a case report and review of literature. Clinical Rheumatology, 2016, 35, 1377-1382. | 2.2 | 35 |
| 98 | Contact allergy in chronic eczematous lip dermatitis. European Journal of Dermatology, 2008, 18, 688-92. | 0.6 | 35 |
| 99 | Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare. JAMA Dermatology, 2022, 158, 375. | 4.1 | 35 |
| 100 | Experimental metagenomics and ribosomal profiling of the human skin microbiome. Experimental Dermatology, 2017, 26, 211-219. | 2.9 | 34 |
| 101 | State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Current Opinion in Pharmacology, 2019, 46, 90-99. | 3 . 5 | 34 |
| 102 | Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. Dermatology and Therapy, 2021, 11, 235-252. | 3.0 | 34 |
| 103 | Heat urticaria: a revision of published cases with an update on classification and management. British Journal of Dermatology, 2016, 175, 473-478. | 1.5 | 32 |
| 104 | Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis. Journal of Immunology Research, 2018, 2018, 1-18. | 2.2 | 32 |
| 105 | C-Reactive Protein and Markers for Thrombophilia in Patients with Chronic Plaque Psoriasis. International Journal of Immunopathology and Pharmacology, 2010, 23, 1195-1202. | 2.1 | 31 |
| 106 | Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 863-869. | 2.4 | 31 |
| 107 | Autoimmune progesterone dermatitis. Gynecological Endocrinology, 2006, 22, 54-56. | 1.7 | 30 |
| 108 | Histiocytoid Sweet syndrome is infiltrated predominantly by M2-like macrophages. Journal of the American Academy of Dermatology, 2015, 72, 131-139. | 1.2 | 30 |

| # | Article | IF | CITATIONS |
|-----|--|--------------|-----------|
| 109 | Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. European Journal of Dermatology, 2017, 27, 599-608. | 0.6 | 30 |
| 110 | Advanced Glycation End Products are Increased in the Skin and Blood of Patients with Severe Psoriasis. Acta Dermato-Venereologica, 2017, 97, 782-787. | 1.3 | 30 |
| 111 | Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. Journal of Dermatological Treatment, 2018, 29, 217-219. | 2.2 | 30 |
| 112 | Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study. Journal of the American Academy of Dermatology, 2019, 81, 403-411. | 1.2 | 29 |
| 113 | Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies. Vaccines, 2020, 8, 769. | 4.4 | 29 |
| 114 | A systematic review of treatments for pityriasis lichenoides. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 2039-2049. | 2.4 | 28 |
| 115 | Management of patients with atopic dermatitis undergoing systemic therapy during COVIDâ€19 pandemic in Italy: Data from the DAâ€COVIDâ€19 registry. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1813-1824. | 5 . 7 | 28 |
| 116 | Psoriasis is not associated with cognition, brain imaging markers, and risk for dementia: The Rotterdam Study. Journal of the American Academy of Dermatology, 2021, 85, 671-680. | 1.2 | 27 |
| 117 | Paradoxical psoriasis induced by TNFâ€Î± blockade shows immunological features typical of the early phase of psoriasis development. Journal of Pathology: Clinical Research, 2020, 6, 55-68. | 3.0 | 27 |
| 118 | The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments. Vaccines, 2020, 8, 728. | 4.4 | 27 |
| 119 | Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug Design, Development and Therapy, 2016, 10, 1763. | 4.3 | 26 |
| 120 | Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study. British Journal of Dermatology, 2018, 178, e215-e216. | 1.5 | 26 |
| 121 | Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. Journal of Dermatological Treatment, 2020, 31, 794-800. | 2.2 | 26 |
| 122 | Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. Journal of Endocrinological Investigation, 2022, 45, 1277-1288. | 3.3 | 26 |
| 123 | Measuring psoriatic disease in clinical practice. An expert opinion position paper. Autoimmunity Reviews, 2015, 14, 864-874. | 5.8 | 25 |
| 124 | The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar. Current Medical Research and Opinion, 2017, 33, 993-1003. | 1.9 | 25 |
| 125 | Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Italian Journal of Dermatology and Venereology, 2022, 157, 1-78. | 0.2 | 25 |
| 126 | Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16â€week realâ€life experience during the <scp>COVID</scp> â€19 pandemic in Italy. Dermatologic Therapy, 2021, 34, e15035. | 1.7 | 24 |

| # | Article | IF | CITATIONS |
|-----|--|-------------|-----------|
| 127 | Subacute Cutaneous Lupus Erythematosus Induced by Nifedipine. Journal of Cutaneous Medicine and Surgery, 2003, 7, 243-246. | 1.2 | 23 |
| 128 | A patientâ€centred approach to biological treatment decision making for psoriasis: an expert consensus. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2390-2398. | 2.4 | 23 |
| 129 | Role of MyD88 signaling in the imiquimod-induced mouse model of psoriasis: focus on innate myeloid cells. Journal of Leukocyte Biology, 2017, 102, 791-803. | 3.3 | 23 |
| 130 | The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opinion on Pharmacotherapy, 2019, 20, 863-872. | 1.8 | 23 |
| 131 | Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32â€week realâ€world experience during the COVIDâ€19 pandemic. Clinical and Experimental Dermatology, 2022, 47, 165-167. | 1.3 | 23 |
| 132 | Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. Medical Ultrasonography, 2018, 20, 177. | 0.8 | 23 |
| 133 | Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 22-32. | 2.4 | 22 |
| 134 | <i>HLA-Cw6</i> and other HLA-C alleles, as well as <i>MICB-DT, DDX58,</i> and <i>TYK2</i> genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. Expert Opinion on Biological Therapy, 2021, 21, 259-270. | 3.1 | 22 |
| 135 | Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. Biologics: Targets and Therapy, 2021, Volume 15, 247-253. | 3.2 | 22 |
| 136 | Adalimumab in severe plaque psoriasis of childhood: A multiâ€center, retrospective realâ€ife study up to 52 weeks observation. Dermatologic Therapy, 2019, 32, e13091. | 1.7 | 21 |
| 137 | Secukinumab shows high efficacy irrespective of <i>HLAâ€Cw6</i> status in patients with moderateâ€toâ€severe plaqueâ€type psoriasis: results from extension phase of the SUPREME study. British Journal of Dermatology, 2019, 181, 413-414. | 1.5 | 21 |
| 138 | Medikamenteninduzierter Lupus erythematodes unter besonderer BerÃ⅓cksichtigung von Hautmanifestationen und Antiâ€₹NFαâ€₹herapeutika. JDDG - Journal of the German Society of Dermatology, 2012, 10, 889-897. | 0.8 | 20 |
| 139 | The Cost Effectiveness of Biologic Therapy for the Treatment of Chronic Plaque Psoriasis in Real Practice Settings in Italy. BioDrugs, 2014, 28, 285-295. | 4. 6 | 20 |
| 140 | Intralymphatic Histiocytosis: A case report and review of literature. Journal of Cutaneous Pathology, 2015, 42, 593-599. | 1.3 | 20 |
| 141 | European Guidelines (S1) on the use of highâ€dose intravenous immunoglobulin in dermatology. JDDG - Journal of the German Society of Dermatology, 2017, 15, 228-241. | 0.8 | 20 |
| 142 | Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. Rheumatology and Therapy, 2020, 7, 271-285. | 2.3 | 20 |
| 143 | Impact of the COVIDâ€19 pandemic on melanoma diagnosis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e714-e715. | 2.4 | 20 |
| 144 | Intracellular Insulin-like growth factor binding protein 2 (IGFBP2) contributes to the senescence of keratinocytes in psoriasis by stabilizing cytoplasmic p21. Aging, 2020, 12, 6823-6851. | 3.1 | 20 |

| # | Article | IF | Citations |
|-----|---|-----|-----------|
| 145 | Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. Clinical and Experimental Rheumatology, 2019, 37, 133-136. | 0.8 | 20 |
| 146 | Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. British Journal of Dermatology, 2017, 177, e325-e326. | 1.5 | 19 |
| 147 | A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. Journal of Dermatological Treatment, 2022, 33, 1146-1149. | 2.2 | 19 |
| 148 | Keratinocytes in skin inflammation. Expert Review of Dermatology, 2006, 1, 279-291. | 0.3 | 18 |
| 149 | A cream based on Aquaphilus dolomiae extracts alleviates non-histaminergic pruritus in humans. European Journal of Dermatology, 2017, 27, 317-318. | 0.6 | 18 |
| 150 | Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biologics: Targets and Therapy, 2018, Volume 12, 151-158. | 3.2 | 18 |
| 151 | TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Review of Clinical Immunology, 2020, 16, 591-598. | 3.0 | 18 |
| 152 | Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA). Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 1-7. | 0.8 | 18 |
| 153 | Cost-effectiveness analysis of TNF-α blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. Dermatologic Therapy, 2010, 23, S7-S13. | 1.7 | 17 |
| 154 | Treatment of psoriasis with etanercept: the typical patient profile. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1092-1099. | 2.4 | 17 |
| 155 | Etanercept biosimilar <scp>SB</scp> 4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. British Journal of Dermatology, 2019, 180, 409-410. | 1.5 | 17 |
| 156 | Switching from one infliximab biosimilar (CTâ€P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. British Journal of Dermatology, 2020, 183, 397-398. | 1.5 | 17 |
| 157 | The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on <scp>I</scp> talian actual clinical practice. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2411-2416. | 2.4 | 16 |
| 158 | Public perception of dermatology and dermatologists in Italy: results from a populationâ€based national survey. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 2119-2123. | 2.4 | 16 |
| 159 | Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. Advances in Therapy, 2018, 35, 545-562. | 2.9 | 16 |
| 160 | Keratosis lichenoides chronica. Dermatology, 2000, 201, 261-264. | 2.1 | 15 |
| 161 | Prurigo pigmentosa in a pregnant woman. International Journal of Gynecology and Obstetrics, 2007, 98, 261-262. | 2.3 | 15 |
| 162 | Concept of Remission in Chronic Plaque Psoriasis. Journal of rheumatology Supplement, The, 2015, 93, 57-60. | 2.2 | 15 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Consensus on the management of patients with psoriatic arthritis in a dermatology setting. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 515-528. | 2.4 | 15 |
| 164 | Drug survival of dupilumab compared to cyclosporin in moderateâ€toâ€severe atopic dermatitis patients. Dermatologic Therapy, 2020, 33, e13979. | 1.7 | 15 |
| 165 | Phosphatidylserine enhances the ability of epidermal Langerhans cells to induce contact hypersensitivity. Journal of Immunology, 1993, 150, 4236-43. | 0.8 | 15 |
| 166 | Pemphigus vulgaris Following Cobalt Therapy for Bronchial Carcinoma. Dermatology, 1989, 178, 37-38. | 2.1 | 14 |
| 167 | Subacute Cutaneous Lupus Erythematosus Induced by Nifedipine. Journal of Cutaneous Medicine and Surgery, 2003, 7, 243-246. | 1.2 | 14 |
| 168 | Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel. Journal of Dermatological Treatment, 2015, 26, 128-133. | 2.2 | 14 |
| 169 | Primary Cutaneous CD4 ⁺ Small/Medium Pleomorphic T-Cell Lymphoproliferative Disorder: A Case Series. Journal of Cutaneous Medicine and Surgery, 2017, 21, 502-506. | 1.2 | 14 |
| 170 | ILâ€17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review. Dermatologic Therapy, 2021, 34, e14889. | 1.7 | 14 |
| 171 | Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study. European Journal of Dermatology, 2018, 28, 44-49. | 0.6 | 14 |
| 172 | Clinical features and course of cutaneous mastocytosis in 133 children. British Journal of Dermatology, 2016, 174, 411-413. | 1.5 | 13 |
| 173 | Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks. Journal of Clinical Medicine, 2020, 9, 3594. | 2.4 | 13 |
| 174 | Flare management in atopic dermatitis: from definition to treatment. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232110667. | 2.5 | 13 |
| 175 | Facial basal cell carcinomas treated with hypo-fractionated radiotherapy: A retrospective analysis in 117 elderly patients. Journal of the American Academy of Dermatology, 2015, 73, 166-168. | 1.2 | 12 |
| 176 | Impact of training on concordance among rheumatologists and dermatologists in the assessment of patients with psoriasis and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2016, 46, 305-311. | 3.4 | 12 |
| 177 | Keratosis lichenoides chronica: Case-based review of treatment options. Journal of Dermatological Treatment, 2016, 27, 383-388. | 2.2 | 12 |
| 178 | Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 294-303. | 2.4 | 12 |
| 179 | Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. Dermatologic Therapy, 2020, 33, e14281. | 1.7 | 12 |
| 180 | Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis. Giornale Italiano Di Dermatologia E Venereologia, 2012, 147, 609-24. | 0.8 | 12 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Patients with Psoriasis Have a Higher Prevalence of Parental Cardiovascular Disease. Dermatology, 2011, 222, 330-335. | 2.1 | 11 |
| 182 | Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel. Allergologia Et Immunopathologia, 2019, 47, 194-206. | 1.7 | 11 |
| 183 | Psoriasin (S100A7) is increased in the serum of patients with moderateâ€toâ€severe psoriasis. British Journal of Dermatology, 2020, 182, 1502-1503. | 1.5 | 11 |
| 184 | Non-Melanoma Skin Cancer in Outdoor Workers: A Study on Actinic Keratosis in Italian Navy Personnel. International Journal of Environmental Research and Public Health, 2020, 17, 2321. | 2.6 | 11 |
| 185 | Contact allergy in children with and without atopic dermatitis: An Italian multicentre study. Contact Dermatitis, 2022, 87, 265-272. | 1.4 | 11 |
| 186 | Skin rash and arthritis a simplified appraisal of less common associations. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 679-688. | 2.4 | 10 |
| 187 | The pruritogenic role of the type 2 immune response in diseases associated with chronic itch. Experimental Dermatology, 2021, 30, 1208-1217. | 2.9 | 10 |
| 188 | Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis. Clinical Drug Investigation, 2021, 41, 1011-1020. | 2.2 | 10 |
| 189 | Real life longâ€term efficacy and safety of ixekizumab in moderateâ€toâ€severe psoriasis: A 192 weeks multicentric retrospective study— <scp>lL PSO</scp> (<scp>ltalian</scp> landscape psoriasis). Dermatologic Therapy, 2022, 35, . | 1.7 | 10 |
| 190 | Monkeypox virus infection: what dermatologist needs to know?. Journal of the European Academy of Dermatology and Venereology, 2022, 36, . | 2.4 | 10 |
| 191 | Metastatic Crohn's disease in childhood. JDDG - Journal of the German Society of Dermatology, 2016, 14, 431-434. | 0.8 | 9 |
| 192 | Fusidic acid betamethasone lipid cream. International Journal of Clinical Practice, 2016, 70, 4-13. | 1.7 | 9 |
| 193 | Pediatric CD8+/CD56+ mycosis fungoides with cytotoxic marker expression: A variant with indolent course. Journal of Cutaneous Pathology, 2018, 45, 782-785. | 1.3 | 9 |
| 194 | Back to the future: a new topical approach for mild-to-moderate psoriasis. Italian Journal of Dermatology and Venereology, 2018, 153, 375-382. | 0.2 | 9 |
| 195 | Increased red blood cell distribution width in patients with plaque psoriasis. Journal of Medical Biochemistry, 2021, 40, 199-201. | 1.7 | 9 |
| 196 | Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer. Dermatology, 2021, 237, 1-5. | 2.1 | 9 |
| 197 | Topical tacrolimus in adult atopic dermatitis: a consensus based on a 15-year experience. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 8-13. | 0.8 | 9 |
| 198 | Psoriasis and Metabolic Comorbidities: The Importance of Well-Designed Prospective Studies. Dermatology, 2008, 217, 222-224. | 2.1 | 8 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Experimental elicitation of itch: Evoking and evaluation techniques. Journal of Dermatological Science, 2015, 80, 13-17. | 1.9 | 8 |
| 200 | Glomerular filtration rate in patients with psoriasis treated with etanercept. Journal of International Medical Research, 2016, 44, 106-108. | 1.0 | 8 |
| 201 | Interferon-beta injection site reactions in patients with multiple sclerosis. Journal of Dermatological Treatment, 2018, 29, 831-834. | 2.2 | 8 |
| 202 | Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission. British Journal of Dermatology, 2019, 181, 1319-1320. | 1.5 | 8 |
| 203 | Clinical features and treatments of transient acantholytic dermatosis (Grover's disease): a systematic review. JDDG - Journal of the German Society of Dermatology, 2020, 18, 826-833. | 0.8 | 8 |
| 204 | Brodalumab in the treatment of chronic plaque psoriasis. Expert Opinion on Biological Therapy, 2020, 20, 1175-1186. | 3.1 | 8 |
| 205 | Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis. Journal of the American Academy of Dermatology, 2021, , . | 1.2 | 8 |
| 206 | The burden of atopic dermatitis in adults in Italy. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 19-23. | 0.8 | 8 |
| 207 | Biological agents targeting interleukin-13 for atopic dermatitis. Expert Opinion on Biological Therapy, 2022, 22, 651-659. | 3.1 | 8 |
| 208 | Upadacitinib in patients with resistant atopic dermatitis: a retrospective caseâ€series. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1499-1500. | 2.4 | 8 |
| 209 | Dupilumab for recalcitrant Kimura disease. Dermatologic Therapy, 2022, 35, . | 1.7 | 8 |
| 210 | Preheated autologous serum skin test in localized heat urticaria. Clinical and Experimental Dermatology, 2014, 39, 921-923. | 1.3 | 7 |
| 211 | Metastatischer Morbus Crohn in der Kindheit. JDDG - Journal of the German Society of Dermatology, 2016, 14, 431-434. | 0.8 | 7 |
| 212 | Long-term efficacy of high doses of intravenous immunoglobulins in generalized scleromyxoedema: Case report. Journal of International Medical Research, 2016, 44, 109-112. | 1.0 | 7 |
| 213 | Patients' perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Journal of Dermatological Treatment, 2017, 28, 390-393. | 2.2 | 7 |
| 214 | Kyrle's disease effectively treated with oral isotretinoin. Journal of Dermatological Treatment, 2018, 29, 630-632. | 2.2 | 7 |
| 215 | Lysyl oxidase-like-2 mutations and reduced mRNA and protein expression in mid-dermal elastolysis. Clinical and Experimental Dermatology, 2019, 44, 47-51. | 1.3 | 7 |
| 216 | Unmet needs in atopic dermatitis management: an expert consensus. Journal of Dermatological Treatment, 2022, 33, 2459-2465. | 2.2 | 7 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference. Giornale Italiano Di Dermatologia E Venereologia, 2014, 149, 607-25. Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian | 0.8 | 7 |
| 218 | Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Italian Journal of | 0.2 | 7 |
| 219 | Dermatology and Venereology, 2022, 157, . Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi TM): a multidisciplinary perspective. Expert Opinion on Biological Therapy, 2022, 22, 109-121. | 3.1 | 7 |
| 220 | Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis. Dermatology and Therapy, 2022, 12, 1303-1311. | 3.0 | 7 |
| 221 | Kaposi's sarcoma with primary bone lesions in an HIV-seronegative man. British Journal of Dermatology, 1996, 134, 966-969. | 1.5 | 6 |
| 222 | Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. Dermatology, 2009, 219, 158-161. | 2.1 | 6 |
| 223 | Single organ cutaneous vasculitis: Case definition & Samp; guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2016, 34, 6561-6571. | 3.8 | 6 |
| 224 | Certolizumab for the treatment of psoriasis and psoriatic arthritis: a realâ€world multicentre Italian study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2839-2845. | 2.4 | 6 |
| 225 | Consensus on the place in therapy of TNFâ€Î± inhibitors in the treatment of patients with chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e470-e472. | 2.4 | 6 |
| 226 | A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. Expert Review of Clinical Pharmacology, 2020, 13, 481-491. | 3.1 | 6 |
| 227 | Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis. Expert Opinion on Biological Therapy, 2022, 22, 1579-1584. | 3.1 | 6 |
| 228 | Sharing Patient and Clinician Experiences of Moderate-to-Severe Psoriasis: A Nationwide Italian Survey and Expert Opinion to Explore Barriers Impacting upon Patient Wellbeing. Journal of Clinical Medicine, 2022, 11, 2801. | 2.4 | 6 |
| 229 | Lysyl oxidase-like 2 promoter hypermethylation in mid-dermal elastolysis. British Journal of Dermatology, 2016, 175, 1354-1356. | 1.5 | 5 |
| 230 | BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. British Journal of Dermatology, 2019, 180, 933-934. | 1.5 | 5 |
| 231 | Non-Bullous Pemphigoid: A Single-Center Retrospective Study. Dermatology, 2021, 237, 1039-1045. | 2.1 | 5 |
| 232 | Alopecic and aseptic nodules of the scalp: A new case with a systematic review of the literature. Clinical Case Reports (discontinued), 2021, 9, e04153. | 0.5 | 5 |
| 233 | Acquired perforating dermatoses show increased levels of cutaneous advanced glycation endâ€products. Clinical and Experimental Dermatology, 2022, 47, 80-85. | 1.3 | 5 |
| 234 | Primary nodular localized cutaneous amyloidosis of the scalp associated with systemic lupus erythematosus. Archives of Rheumatology, 2022, 37, 145-147. | 0.9 | 5 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Cutaneous necrosis complicating the injection of pegylated interferon alpha-2b in a patient with chronic hepatitis C. Acta Dermatovenerologica Croatica, 2008, 16, 35-7. | 0.1 | 5 |
| 236 | Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. Vaccines, 2022, 10, 646. | 4.4 | 5 |
| 237 | Public perception of dermatology and dermatologists: a very relevant but untapped issue. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1950-1950. | 2.4 | 4 |
| 238 | Glomerular filtration rate in patients with moderateâ€toâ€severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e244-e246. | 2.4 | 4 |
| 239 | Mortality from cancer is not increased in elderly kidney transplant recipients compared to the general population: a competing risk analysis. Journal of Nephrology, 2020, 33, 1309-1319. | 2.0 | 4 |
| 240 | Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab. Dermatologic Therapy, 2020, 33, e13967. | 1.7 | 4 |
| 241 | Satisfaction and attitudes toward systemic treatments for psoriasis: A crossâ€sectional study. Dermatologic Therapy, 2021, 34, e14949. | 1.7 | 4 |
| 242 | Assessing patients' characteristics and treatment patterns among children with atopic dermatitis. Italian Journal of Pediatrics, 2021, 47, 92. | 2.6 | 4 |
| 243 | Undertreatment in adult patients with moderateâ€toâ€severe atopic dermatitis and other chronic inflammatory skin diseases. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2168-2169. | 2.4 | 4 |
| 244 | Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis. Journal of Personalized Medicine, 2021, 11, 1069. | 2.5 | 4 |
| 245 | Biosimilar infliximab: an expert view. Giornale Italiano Di Dermatologia E Venereologia, 2015, 150, 449-59. | 0.8 | 4 |
| 246 | Analisi di budget impact del biosimilare di etanercept: lo scenario italiano. Global & Regional Health Technology Assessment, 2018, 2018, 228424031876680. | 0.1 | 3 |
| 247 | Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. British Journal of Dermatology, 2019, 182, 175-179. | 1.5 | 3 |
| 248 | Relapse of psoriatic arthritis in patients with active psoriasis switched from tumour necrosis factorâ€Î± to interleukinâ€17A inhibitor. British Journal of Dermatology, 2019, 181, 624-626. | 1.5 | 3 |
| 249 | Low dose acitretin versus methotrexate in the treatment of palmoplantar psoriasis: a case series. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e246-e247. | 2.4 | 3 |
| 250 | A case of kerion celsi caused by <i>Trichophyton tonsurans</i> . Pediatrics International, 2020, 62, 1007-1008. | 0.5 | 3 |
| 251 | Place of apremilast in the realâ€life treatment of patients with plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 13-13. | 2.4 | 3 |
| 252 | Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines. Giornale Italiano Di Dermatologia E Venereologia, 2016, 151, 432-5. | 0.8 | 3 |

| # | Article | IF | Citations |
|-----|---|-----|-----------|
| 253 | Is risankizumab as needed administration a good option for patients with plaque psoriasis?. Journal of the European Academy of Dermatology and Venereology, 2022, 36, . | 2.4 | 3 |
| 254 | Focus on psoriatic arthritis and comorbidities. Expert Review of Dermatology, 2008, 3, S35-S36. | 0.3 | 2 |
| 255 | Classifying immunopathological responses in chronic inflammatory skin diseases. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 654-655. | 2.4 | 2 |
| 256 | The multifaceted association between psoriasis and obesity. British Journal of Dermatology, 2019, 180, 24-24. | 1.5 | 2 |
| 257 | Job: the prototypic dermatological patient. Comments on a painting by Marcello Fogolino. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2175-2176. | 2.4 | 2 |
| 258 | Is SARSâ€CoVâ€2 screening test indicated for psoriasis patients candidate to biologic therapy?. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e355-e357. | 2.4 | 2 |
| 259 | Adrenergic urticaria successfully treated with omalizumab. Journal of Dermatology, 2021, 48, e541-e542. | 1.2 | 2 |
| 260 | Clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Italian Journal of Dermatology and Venereology, 2021, 156, 455-459. | 0.2 | 2 |
| 261 | Amicrobial pustulosis of the folds: Report of three new cases. Indian Journal of Dermatology, 2020, 65, 323. | 0.3 | 2 |
| 262 | Nivolumab induced morphea. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 701-702. | 0.8 | 2 |
| 263 | The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clinical and Experimental Rheumatology, 2021, 39, 1099-1107. | 0.8 | 2 |
| 264 | AB0821â€Baseline Characteristics of Patients with Moderate to Severe Psoriatic Arthritis: Post-Hoc Analysis of Responders vs Non-Responders to Etanercept. Annals of the Rheumatic Diseases, 2015, 74, 1174-1174. | 0.9 | 1 |
| 265 | Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches. Expert Opinion on Investigational Drugs, 2018, 27, 699-707. | 4.1 | 1 |
| 266 | Visual Vignette. Endocrine Practice, 2020, 26, 253. | 2.1 | 1 |
| 267 | Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination. Vaccine, 2020, 38, 3808-3809. | 3.8 | 1 |
| 268 | Characteristics associated with clinical response to Comano thermal spring water balneotherapy in pediatric patients with atopic dermatitis. Italian Journal of Pediatrics, 2021, 47, 91. | 2.6 | 1 |
| 269 | Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature. Case Reports in Dermatology, 2021, 13, 282-288. | 0.8 | 1 |
| 270 | Hypochondriasis and Personality Traits of Patients with Chronic Plaque Psoriasis. Dermatology, 2022, 238, 276-282. | 2.1 | 1 |

| # | Article | IF | Citations |
|-----|---|-----|-----------|
| 271 | Predictors of subsequent primary melanoma: a case–control study. Archives of Dermatological Research, 2022, 314, 881-885. | 1.9 | 1 |
| 272 | Clinical profile and co-infections of urethritis in males. Italian Journal of Dermatology and Venereology, 2021, , . | 0.2 | 1 |
| 273 | Skin adverse reactions to Sarsâ€CoVâ€2 vaccination: a relevant responsibility issue for dermatologists. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 165-166. | 2.4 | 1 |
| 274 | Tongue flap to treat a severe case of Miescher's cheilitis granulomatosa. Minerva Stomatologica: A Journal on Dentirstry and Maxillofacial Surgery, 2013, 62, 79-86. | 1.3 | 1 |
| 275 | Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis. Journal of Cutaneous Medicine and Surgery, 2021, , 120347542110669. | 1.2 | 1 |
| 276 | Exfoliative cheilitis as a manifestation of factitial cheilitis in a young man. Italian Journal of Dermatology and Venereology, 2021, 156, 513-514. | 0.2 | 1 |
| 277 | A case of porokeratosis with predominant follicular involvement. Italian Journal of Dermatology and Venereology, 2021, 156, 619-620. | 0.2 | 1 |
| 278 | Skin moisturization for xerosis related to targeted anticancer therapies. Journal of the American Academy of Dermatology, 2015, 73, e33. | 1.2 | 0 |
| 279 | Severe cutaneous aluminum reaction to quadrivalent human papillomavirus vaccine treated with cyclosporin. Journal of Dermatology, 2017, 44, e332-e333. | 1.2 | 0 |
| 280 | Segregation analysis revealed hemizygotic causative mutations in a pseudoxanthoma elasticum patient. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e365-e366. | 2.4 | 0 |
| 281 | Image Gallery: Pyoderma gangrenosum of the penis. British Journal of Dermatology, 2018, 178, e62. | 1.5 | 0 |
| 282 | Coexistence of scleromyxedema and Sneddon syndrome. JAAD Case Reports, 2021, 11, 47-50. | 0.8 | 0 |
| 283 | A case of genital primary syphilis with superimposed impetigo. Italian Journal of Dermatology and Venereology, 2021, , . | 0.2 | 0 |
| 284 | Reply to: Non-Bullous Pemphigoid: A Yet-to-Be Defined Disease Entity. Dermatology, 2021, 237, 1-2. | 2.1 | 0 |
| 285 | Bleomycin-induced Flagellate Dermatitis: a Case Report. Serbian Journal of Dermatology and Venereology, 2020, 12, 15-18. | 0.2 | 0 |
| 286 | Lymphoplasmacitic plaque effectively treated with imiquimod. Italian Journal of Dermatology and Venereology, $2019, , .$ | 0.2 | 0 |
| 287 | Idiopathic lichenoid and granulomatous dermatitis. Italian Journal of Dermatology and Venereology, 2020, , . | 0.2 | 0 |
| 288 | Therapeutic management of chronic spontaneous urticaria in clinical practice: results from a pilot survey. Italian Journal of Dermatology and Venereology, 2020, , . | 0.2 | 0 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Chronic spontaneous urticaria in clinical practice: a pilot survey about attitudes and perceptions on assessment, diagnostic work-up and dietary management. Italian Journal of Dermatology and Venereology, 2020, , . | 0.2 | 0 |
| 290 | The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases. Italian Journal of Dermatology and Venereology, 2022, , . | 0.2 | 0 |
| 291 | Dermoscopic features of nevoid melanoma: a retrospective study with systematic literature review. Italian Journal of Dermatology and Venereology, 2022, , . | 0.2 | 0 |
| 292 | Reduction of cutaneous advanced glycation end products levels after effective psoriasis treatment. Journal of the European Academy of Dermatology and Venereology, 2022, 36, . | 2.4 | 0 |
| 293 | Variations of symptoms of atopic dermatitis and psoriasis in relation to menstrual cycle. Journal of the American Academy of Dermatology, 2021, , . | 1.2 | 0 |